enGene Holdings Inc.

ENGN · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
61
SEC Filings

Business Summary

Competition for additional information. The genetic medicine field is relatively new and evolving rapidly. Because of our limited technical, financial and human resources, we are focusing our research and development efforts on detalimogene, as well as further development of our genetic medicine platform and other product candidates we may develop. As a result, we may forego or delay pursuit of other genetic medicine technologies or other therapeutic product candidates that provide significant a...

Next Earnings

Q2 FY2026 — expected 2026-09-12

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionENGNdiscussed_in_filing Cybersecurity
topic_mentionENGNdiscussed_in_filing Cybersecurity
topic_mentionENGNdiscussed_in_filing Healthcare & Bio
topic_mentionENGNdiscussed_in_filing Platform & Ecosystem
topic_mentionENGNdiscussed_in_filing Healthcare & Bio
topic_mentionENGNdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-12-222025-10-310001193125-25-328743EDGAR107K words
2024-12-192024-10-310000950170-24-138472EDGAR—
2024-01-292023-10-310000950170-24-008125EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-03-092026-01-310001193125-26-097541EDGAR24K words
2025-09-112025-07-310000950170-25-114224EDGAR—
2025-06-122025-04-300000950170-25-085143EDGAR—
2025-03-102025-01-310000950170-25-036281EDGAR—
2024-09-102024-07-310000950170-24-105180EDGAR—
2024-06-142024-04-300000950170-24-073330EDGAR—
2024-03-112024-01-310000950170-24-029413EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-090001193125-26-097546EDGAR26K words
2026-03-090001193125-26-097534EDGAR—
2026-01-210001193125-26-017945EDGAR—
2026-01-210001193125-26-017226EDGAR—
2025-12-220001193125-25-328706EDGAR—
2025-11-140001193125-25-283182EDGAR—
2025-11-120001193125-25-275722EDGAR—
2025-10-020001193125-25-228351EDGAR—
2025-09-300001193125-25-224053EDGAR—
2025-09-110000950170-25-114220EDGAR—

61 total filings indexed. 41 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001980845
TickerENGN
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedZ4

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 877854aa1e48e4a41d29976979f04afd97efb49af05b8e43cd4f2dc7dae92af5
parent: 4072bdb16acf917288cc5e9ed171f330399779757e150e39deafe3d76ba53537
content hash: 1fbf8b90d9866c1e7239f9999915853be1b8789f0da31e5ef0519fc0eebd976c
signed: 2026-04-13T04:44:51.744Z
sources: 10 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf